High throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing.

Area of Science:

• Biomedical Engineering
• Oncology
• Drug Discovery

Background:

• Traditional 2D cell cultures limit the efficiency and accuracy of oncology drug screening.
• There is a need for improved 3D models that better mimic in vivo tumor environments.

Purpose of the Study:

• To develop and validate a 3D micro-tumor array (3D-MTA) for high-throughput oncology drug screening.
• To compare the predictive accuracy of 3D-MTA with 2D cultures for in vivo drug responses.
• To demonstrate the utility of 3D-MTA in modeling drug resistance and identifying synergistic drug combinations.

Main Methods:

• Generation of uniform 3D micro-tumor arrays (3D-MTA) in a 384-well format using micro-scaffolds.
• Screening of chemotherapeutic agents (doxorubicin, gemcitabine, vinorelbine) and targeted therapy (gefitinib) using 3D-MTA and 2D cultures.
• Modeling drug resistance and synergistic effects using patient-derived cells and xenografts.
• Compatibility assessment with standard high-throughput and high-content screening instruments.

Main Results:

• 3D-MTA achieved uniform tumor formation (CV < 0.15) and high screen quality (Z' > 0.5).
• 3D-MTA accurately predicted in vivo drug responses, identifying doxorubicin's efficacy while 2D cultures failed to distinguish ineffective drugs (gemcitabine, vinorelbine).
• 3D-MTA successfully modeled gefitinib resistance and identified pisamertinib as a synergistic agent with gefitinib.
• Drug response concordance was confirmed between 3D-MTA and in vivo studies using patient-derived cells and xenografts.

Conclusions:

• 3D micro-tumor arrays offer a robust and accurate platform for high-throughput oncology drug screening.
• This 3D model significantly improves the prediction of in vivo drug efficacy and resistance compared to 2D cultures.
• 3D-MTA holds strong potential to accelerate cancer drug discovery and enhance therapeutic strategies.